RESUMO
A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed is whether thymomectomy can be equivalent to thymectomy for non-myasthenic early-stage thymoma in terms of recurrence and survival. Ten papers were chosen to answer the question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers were tabulated. All studies included in this analysis are retrospective; most of them are small and from single-institution experiences, and only 3 used propensity-matched analysis to minimize the patients' selection bias. The choice of performing thymectomy or thymomectomy was based on surgeons' preference rather than on a standardized surgical approach. Most papers found that thymectomy was equivalent to thymomectomy in terms of outcomes, but these results could be affected by the intergroup differences in terms of follow-up length, administration of induction or adjuvant therapy, histological subtypes distribution and tumour size. Conversely, the studies of the Japanese Association for Research on the Thymus and the Chinese Alliance for Research in Thymoma found a higher rate of local recurrence in the thymomectomy group than in the thymectomy group. The National Comprehensive Cancer Network, National Cancer Institute and International Thymic Malignancy Interest Group recommend complete thymectomy in non-myasthenic patients with early thymoma; therefore, the identified studies in this review are not strong enough to change this recommendation.
Assuntos
Estadiamento de Neoplasias , Timectomia/métodos , Timoma/cirurgia , Neoplasias do Timo/cirurgia , Feminino , Humanos , Pessoa de Meia-Idade , Timoma/diagnóstico , Neoplasias do Timo/diagnósticoRESUMO
Several surgical procedures, from debulking to extrapleural pneumonectomy, may be applied for stage IVa Masaoka thymomas, but their efficiency is still controversial. Case studies have favored R0 resection as the cornerstone of multimodal therapy for locoregional metastatic extension. This report describes a standardized procedure combining a cytoreductive surgical procedure and intrathoracic chemohyperthermia on a 46-year-old patient presenting with B2 thymoma and synchronous unilateral pleural metastasis.
Assuntos
Antineoplásicos/uso terapêutico , Procedimentos Cirúrgicos de Citorredução/métodos , Hipertermia Induzida/métodos , Neoplasias Pleurais/terapia , Timectomia/métodos , Timoma/cirurgia , Neoplasias do Timo/cirurgia , Feminino , Humanos , Pessoa de Meia-Idade , Metástase Neoplásica , Estadiamento de Neoplasias , Pleura/cirurgia , Neoplasias Pleurais/diagnóstico , Neoplasias Pleurais/secundário , Pneumonectomia , Timoma/diagnóstico , Timoma/secundário , Neoplasias do Timo/diagnóstico , Tomografia Computadorizada por Raios XRESUMO
BACKGROUND: For thymic epithelial tumors (TETs), the National Comprehensive Cancer Network guideline has suggested that complete excision of the tumor should be performed without a preoperative biopsy when resectable. However, little evidence has been provided to support this strategy. The purpose of this study was to review our diagnostic process and to evaluate the validity of radical resection of anterior mediastinal masses (AMMs) without pathological confirmation. METHODS: A total of 254 patients underwent surgical resection for AMMs between 2004 and 2015. This study included 181 patients with likely TETs according to clinical features, serum levels of tumor markers and autoimmune-antibodies, and radiological findings. In addition, AMMs likely TETs were classified into resectable or unresectable tumors. We retrospectively reviewed the diagnostic process of those patients and validated surgical resection of AMMs without a definitive diagnosis. RESULTS: Among 254 patients, 181 were suspected of having a TET based on the serum levels of tumor markers and autoimmune-antibodies and the radiological findings. Of them, 157 patients were deemed resectable and underwent surgical resection without histological confirmation, and 144 (92%) were diagnosed with TETs in the final pathological examinations. In 13 patients with non-TETs, the tumors were difficult to differentiate from TETs by imaging and clinical findings alone. CONCLUSIONS: A total of 92% of patients suspected of having a TET and who underwent complete resection without pathological confirmation were accurately diagnosed and properly treated. Surgical resection without a definitive diagnosis was feasible in patients suspected of having a TET when they were considered resectable.
Assuntos
Neoplasias do Mediastino/diagnóstico , Neoplasias Epiteliais e Glandulares/diagnóstico , Neoplasias do Timo/diagnóstico , Adolescente , Adulto , Idoso , Biomarcadores Tumorais/sangue , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Neoplasias do Mediastino/patologia , Neoplasias do Mediastino/cirurgia , Pessoa de Meia-Idade , Neoplasias Epiteliais e Glandulares/patologia , Neoplasias Epiteliais e Glandulares/cirurgia , Estudos Retrospectivos , Neoplasias do Timo/patologia , Neoplasias do Timo/cirurgia , Tomografia por Raios XRESUMO
Surgical resection remains the cornerstone of therapy for early-stage thymic epithelial tumors (TETs), while in advanced or recurrent forms, a multimodality approach incorporating radiation and chemotherapy is required. Given the absence of effective treatment options for metastatic/refractory TETs and the poor related prognosis, there is a compelling need to identify promising 'drugable' molecular targets. Initial reports of activity from targeted agents in TETs derived from anecdotal cases have been often associated with specific activating mutations. Only in recent years, several agents have been formally investigated into prospective clinical trials, with varying success rates. We reviewed the literature on targeted therapy in TETs along with two cases of thymoma achieving striking responses to sorafenib in combination with lapatinib.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Terapia de Alvo Molecular , Neoplasias Epiteliais e Glandulares/tratamento farmacológico , Neoplasias Pleurais/tratamento farmacológico , Inibidores de Proteínas Quinases/uso terapêutico , Neoplasias do Timo/tratamento farmacológico , Idoso , Receptores ErbB/antagonistas & inibidores , Feminino , Inibidores de Histona Desacetilases/uso terapêutico , Humanos , Lapatinib , Neoplasias Epiteliais e Glandulares/patologia , Neoplasias Epiteliais e Glandulares/cirurgia , Niacinamida/administração & dosagem , Niacinamida/análogos & derivados , Compostos de Fenilureia/administração & dosagem , Neoplasias Pleurais/secundário , Proteínas Proto-Oncogênicas c-kit/antagonistas & inibidores , Quinazolinas/administração & dosagem , Receptor IGF Tipo 1 , Receptores de Somatomedina/antagonistas & inibidores , Sorafenibe , Serina-Treonina Quinases TOR/antagonistas & inibidores , Neoplasias do Timo/patologia , Neoplasias do Timo/cirurgia , Adulto JovemRESUMO
Thymic carcinoid is a rare disease that accounts for 3.1% of thymic tumors and 1.8-6% of all carcinoid tumors in Japan. Advanced thymic carcinoid has a 5-year survival rate of 28-31%.Compared with carcinoid tumors that arise in other organs, thyroid carcinoid tumors carry a relatively worse prognosis, and the most effective therapeutic strategy is thought to be surgical resection.However, for patients with recurrence and distant metastases, multimodal therapy including radiotherapy and/or chemotherapy is usually applied.No chemotherapy treatment regimen has been established in Japan, although the National Comprehensive Cancer Network Guidelines proposed the application of octreotide long-acting repeatable(LAR).In this report, we present two cases of thymic carcinoid that were treated with octreotide LAR and achieved long-term survival.
Assuntos
Antineoplásicos Hormonais/uso terapêutico , Tumor Carcinoide/tratamento farmacológico , Octreotida/uso terapêutico , Neoplasias do Timo/tratamento farmacológico , Idoso , Tumor Carcinoide/cirurgia , Terapia Combinada , Evolução Fatal , Humanos , Masculino , Neoplasias do Timo/patologia , Neoplasias do Timo/cirurgia , Fatores de TempoRESUMO
Trimodality treatment including induction and/or adjuvant chemotherapy, surgical resection and in some cases radiotherapy offers a curative intention in selected patients with pleural malignancies (malignant pleural mesothelioma, thymoma with pleural spread). Nevertheless, locoregional tumor recurrence mainly limits the outcome and the quality of life. A few years ago an additional intraoperative chemotherapy perfusion was developed in order to improve local tumor control and prognosis after surgical resection in a multimodality treatment setting. Cytoreductive surgery with the purpose of a macroscopic complete resection could be achieved by radical pleurectomy or extrapleural pneumonectomy. The concept, techniques and perioperative management of this additional treatment option are presented along with a detailed review of the recent literature.
Assuntos
Quimioterapia do Câncer por Perfusão Regional/métodos , Terapia Combinada , Hipertermia Induzida/métodos , Pleura/cirurgia , Neoplasias Pleurais/tratamento farmacológico , Neoplasias Pleurais/cirurgia , Pneumonectomia/métodos , Quimioterapia Adjuvante , Cisplatino/administração & dosagem , Cisplatino/efeitos adversos , Cuidados Críticos/métodos , Humanos , Período Intraoperatório , Pleura/patologia , Neoplasias Pleurais/patologia , Neoplasias Pleurais/secundário , Cuidados Pós-Operatórios/métodos , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/mortalidade , Taxa de Sobrevida , Timoma/tratamento farmacológico , Timoma/patologia , Timoma/secundário , Timoma/cirurgia , Neoplasias do Timo/tratamento farmacológico , Neoplasias do Timo/patologia , Neoplasias do Timo/cirurgiaRESUMO
IMPORTANCE OF THE FIELD: Since first reported just over 30 years ago, some progress has been made in our understanding of thymic cancer - an extremely rare cancer - and how to treat it. However, we are far from the ultimate goal of cure for most patients. AREAS COVERED IN THIS REVIEW: This review provides an overview of the thymic gland's development; features of thymic carcinoma, including its molecular characterization, current staging, and treatment guidelines; and progress made to date for treating advanced disease, concluding with future directions and prospects. WHAT THE READER WILL GAIN: As scientists apply new molecular tools to learn more about cancer, we find that even among common cancers, there exist heterogeneous subtypes necessitating different treatment paradigms. Thus, a one-size-fits-all approach to cancer treatment is being displaced with precision medicine to target the 'Achilles heel' of thymic tumors. TAKE HOME MESSAGE: When approaching thymic carcinoma, we must identify the key driving forces to target its context(s) of vulnerability to ensure the greatest impact of treatment for patients with this extremely rare cancer.
Assuntos
Timoma/terapia , Neoplasias do Timo/terapia , Antineoplásicos/uso terapêutico , Terapia Biológica , Cisplatino/uso terapêutico , Ensaios Clínicos como Assunto , Terapia Combinada , Feminino , Genes Supressores de Tumor , Humanos , Masculino , Estadiamento de Neoplasias , Oncogenes , Terapia de Salvação , Timoma/genética , Timoma/patologia , Timoma/cirurgia , Timo/anatomia & histologia , Timo/crescimento & desenvolvimento , Neoplasias do Timo/genética , Neoplasias do Timo/fisiopatologia , Neoplasias do Timo/cirurgiaRESUMO
Recently cytoreductive surgery of primary and secondary pleural tumors has been combined with hyperthermic intrathoracic chemotherapy perfusion (HITHOC) for better local tumor control. In comparison to simple instillation of chemotherapeutic agents into the pleural cavity, the combination of surgical resection of pleural tumors and simultaneous HITHOC seems to be a more effective treatment. Intra-operative perfusion allows an improved distribution of the drug in the pleural space and a higher local concentration of the chemotherapeutic agents in contrast to systemic chemotherapy. Additional advantages of HITHOC are a better response to chemotherapeutic agents and synergistic antineoplastic effects. A prerequisite for safe application of HITHOC is compliance with safety regulations. Due to the reduction in morbidity and mortality this new concept is a valuable alternative for selected patients who do not undergo radical resection (e.g. extrapleural pneumonectomy). HITHOC is an additional therapeutic option in the multimodal treatment of patients with primary or secondary tumors of the pleura.
Assuntos
Antineoplásicos/administração & dosagem , Quimioterapia do Câncer por Perfusão Regional/métodos , Hipertermia Induzida/instrumentação , Mesotelioma/tratamento farmacológico , Mesotelioma/cirurgia , Neoplasias Pleurais/tratamento farmacológico , Neoplasias Pleurais/cirurgia , Timoma/tratamento farmacológico , Timoma/cirurgia , Neoplasias do Timo/tratamento farmacológico , Neoplasias do Timo/cirurgia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Quimioterapia Adjuvante , Terapia Combinada , Humanos , Mesotelioma/patologia , Estadiamento de Neoplasias , Pleura/patologia , Pleura/cirurgia , Neoplasias Pleurais/secundário , Timoma/patologia , Neoplasias do Timo/patologiaAssuntos
Inibidores da Angiogênese/uso terapêutico , Indóis/uso terapêutico , Niacinamida/análogos & derivados , Neoplasias Pleurais/tratamento farmacológico , Neoplasias Pleurais/secundário , Timoma/tratamento farmacológico , Timoma/secundário , Neoplasias do Timo/patologia , Administração Oral , Adulto , Inibidores da Angiogênese/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Quimioterapia Adjuvante , Humanos , Indóis/administração & dosagem , Masculino , Neoplasia Residual/tratamento farmacológico , Niacinamida/administração & dosagem , Niacinamida/uso terapêutico , Oligonucleotídeos , Radioterapia Adjuvante , Timoma/radioterapia , Timoma/cirurgia , Neoplasias do Timo/radioterapia , Neoplasias do Timo/cirurgia , Resultado do TratamentoAssuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Quimioterapia do Câncer por Perfusão Regional , Hipertermia Induzida , Neoplasias Pleurais/tratamento farmacológico , Timoma/tratamento farmacológico , Neoplasias do Timo/tratamento farmacológico , Cisplatino/administração & dosagem , Doxorrubicina/administração & dosagem , Humanos , Cuidados Intraoperatórios , Neoplasias Pleurais/secundário , Neoplasias Pleurais/cirurgia , Radioterapia Adjuvante , Reoperação , Timoma/secundário , Timoma/cirurgia , Neoplasias do Timo/patologia , Neoplasias do Timo/cirurgia , Resultado do TratamentoRESUMO
BACKGROUND: Thymoma and thymic carcinoma with pleural spread have a high rate of locoregional recurrence and poor prognosis. Maximal debulking coupled with aggressive local treatment could offer a chance for cure. This study evaluates the early and midterm results of operation and hyperthermic pleural perfusion with cisplatinum for thymic malignancies. METHODS: Fifteen patients (11 men), 20 to 67 years old (10 thymoma, 4 thymic carcinoma, 1 carcinoma in thymic cyst) underwent resection and hyperthermic pleural perfusion between 1995 to 2000. All had pleural spread proven before or intraoperatively. Six of the thymoma cases were recurrent. Current operation included resection without pleurectomy (9 patients), resection with pleurectomy (5), and extrapleural pneumonectomy (1 patient) with intraoperative hyperthermic pleural perfusion in all. Intrapleural temperature reached 40.3 degrees C to 43 degrees C. The total dose of cisplatinum was 150 mg or more in 14 patients. RESULTS: Complete resection (R0) was achieved in 10 patients, subtotal (R1) in 3, and partial (R2) in 2. There was no operative mortality, no hemodynamic or respiratory disturbances during perfusion, and no hematologic, neurologic, or renal complications. Complications consisted of significant bleeding (2 patients), fever (2), and air leak (1 patient). Two patients with thymic carcinoma died after 27 and 34 months, and 1 is alive with no evidence of disease at 54 months. Two patients with thymoma died after 7 and 36 months. Eight are alive after 9 to 70 months. Four patients (all R0) are alive without local recurrence more than 60 months after operation and hyperthermic pleural perfusion. CONCLUSIONS: Operation and thermochemotherpy is feasible and safe in patients with thymic tumors. This method seems to offer excellent local control for patients with stage IV-a thymic malignancies. Midterm results suggest that operation plus hyperthermic pleural perfusion may lengthen survival in stage IV-a thymoma.
Assuntos
Quimioterapia do Câncer por Perfusão Regional , Cisplatino/administração & dosagem , Hipertermia Induzida , Neoplasias Pleurais/secundário , Timectomia , Timoma/secundário , Neoplasias do Timo/tratamento farmacológico , Adulto , Idoso , Quimioterapia Adjuvante , Terapia Combinada , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/tratamento farmacológico , Recidiva Local de Neoplasia/cirurgia , Neoplasias Pleurais/tratamento farmacológico , Neoplasias Pleurais/cirurgia , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/mortalidade , Reoperação , Taxa de Sobrevida , Timoma/tratamento farmacológico , Timoma/cirurgia , Neoplasias do Timo/cirurgiaRESUMO
Thymic undifferentiated carcinoma has a poor prognosis. We encountered a patient with thymic carcinoma associated with an intrathoracic disseminated lesion, who underwent surgery combined with intrathoracic hyperthermic perfusion after systemic chemotherapy and showed good results. The 45-year-old man was diagnosed as having a thymoma with an intrathoracic disseminated lesion. After he underwent three courses of systemic chemotherapy, he was admitted to our hospital. An anterior mediastinal tumor and an intrathoracic disseminated lesion remained, and were treated by surgical resection combined with intrathoracic hyperthermic perfusion. The tumors were histopathologically diagnosed as thymic undifferentiated carcinomas with pleural dissemination. At present, approximately 16 months after surgery, the patient is alive without recurrence.
Assuntos
Hipertermia Induzida , Neoplasias do Mediastino/terapia , Neoplasias Torácicas/terapia , Timoma/terapia , Neoplasias do Timo/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Terapia Combinada , Intervalo Livre de Doença , Humanos , Masculino , Neoplasias do Mediastino/diagnóstico por imagem , Neoplasias do Mediastino/secundário , Neoplasias do Mediastino/cirurgia , Pessoa de Meia-Idade , Perfusão , Neoplasias Torácicas/diagnóstico por imagem , Neoplasias Torácicas/secundário , Neoplasias Torácicas/cirurgia , Timoma/diagnóstico por imagem , Timoma/cirurgia , Neoplasias do Timo/diagnóstico por imagem , Neoplasias do Timo/cirurgia , Tomografia Computadorizada por Raios X , Resultado do TratamentoRESUMO
According to the theory of traditional Chinese medicine, 37 patients suffering from myasthenia gravis were Syndrome-differentiated into following types preoperationally: (1) Both Qi-Yin Deficiency of Kidney-Spleen, 21 cases. (2) Yang Deficiency of Kidney-Spleen, 15 cases. (3) Qi Deficiency of Spleen only, one case. Thymectomy were done in all cases. Among them, 19 cases had thymoma. The results showed the relationship between the types and the resectionability rate and post-operative crisis rate. On the first two types, they were 95.2% and 9.5%, 46.7% and 73.3% respectively. It was considered that Syndrome differentiation-typing in TCM in the myasthenia gravis patients would provide an positive and reliable index for predicting the resectionability and prognosis of the patient.
Assuntos
Diagnóstico Diferencial , Medicina Tradicional Chinesa , Miastenia Gravis/cirurgia , Timectomia , Adolescente , Adulto , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Miastenia Gravis/complicações , Timoma/complicações , Timoma/cirurgia , Neoplasias do Timo/complicações , Neoplasias do Timo/cirurgiaRESUMO
A 62-year-old woman was admitted to our hospital because of diarrhea and melena. Thymectomy for thymoma with myasthenia gravis was carried out on this patient four years ago. Barium enema revealed four tumor shadows in the ascending and transverse colon. Multiple colon cancer was diagnosed and extended right hemicolectomy was carried out. The postoperative course was uneventful and she has been free from any symptom. In this paper, we discussed the relationship between thymoma and the incidence of nonthymic malignancy.